Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 1, 2004

View Archived Issues

Medarex to receive milestone payment from Amgen for antibody development

Gilead Sciences and Achillion collaborate on HCV compounds

Dyax grants use of antibody phage display libraries to Tanox

Amendment to terms of Vitex/Panacos merger

Progression of Lipid Sciences' Viral Immunotherapy program

Cardiome selects oral controlled-release formulation of RSD-1235

BioMarin plans phase III trial of Phenoptin for 2005

Medivir and Tibotec enter HCV license and research collaboration agreement

Avidia and Boehringer Ingelheim in development and manufacturing agreement

Bleeding associated with serotonin reuptake inhibition

HER2/ERBB3 pathway implicated in hormone refractory prostate cancer

A new prednisolone formulation shows promise in the treatment of UC

Clinical data on the efficacy of fenretinide in recurrent malignant gliomas

Cognitive benefits found with donepezil in MS patients with verbal memory impairment

Groundbreaking study to explore benefits of long-term pimecrolimus treatment

Good safety profile reported for C31G vaginal gel in healthy volunteers

New compounds for the treatment of psychiatric and mood disorders

Merck claims a series of CGRP receptor antagonists

GABA-A receptor modulators described by NeuroSearch

A series of protein tyrosine phosphatase inhibitors described in a patent

Dual acting compounds for the treatment of psychiatric disorders

Novel MAP kinase/TNF inhibitors in early development at Pfizer

Novartis researchers describe beta2-adrenergic agonists

Antibacterial oxazolidinones claimed by Pfizer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...